| |
|
Form Serial Number: |
DA20250731E00433
|
| 1.
Date of relevant event: |
30/07/2025
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
01952 |
| 4.
Name of listed corporation: |
Everest Medicines Limited |
| 5.
Class of shares: |
Ordinary Shares |
| 6.
Number of issued shares in class: |
328,359,043 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
FU |
| (Other names) |
WEI |
|
|
|
| 10.
Name of director (Chinese): |
傅唯 |
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1209 | The number of shares in which you are interested has reduced because:
you placed the shares to placee(s) under a top-up placing |
|
| 2307 | Founder of a discretionary trust who can influence how the trustee exercises his discretion |
|
|
22,561,000 |
HKD |
|
|
69.7000 |
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 84,883,427 | 25.85 |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 62,322,427 | 18.98 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| 2307 | Founder of a discretionary trust who can influence how the trustee exercises his discretion |
| |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| Nova Aqua Limited | British Virgin Islands | VISTRA TRUST (SINGAPORE) PTE. LIMITED | 100.00 | N | |
| TF Capital II, Ltd. | Cayman Islands | Nova Aqua Limited | 47.83 | N | |
| C-Bridge Capital GP, Ltd. | Cayman Islands | TF Capital II, Ltd. | 38.34 | N | |
| C-Bridge Healthcare Fund GP II, L.P. | Cayman Islands | C-Bridge Capital GP, Ltd. | 100.00 | N | |
| C-Bridge Healthcare Fund II, L.P. | Cayman Islands | C-Bridge Healthcare Fund GP II, L.P. | 100.00 | N | |
| C-Bridge Investment Everest Limited | British Virgin Islands | C-Bridge Healthcare Fund II, L.P. | 100.00 | Y | |
| TF Capital IV, Ltd. | Cayman Islands | Nova Aqua Limited | 100.00 | N | |
| C-Bridge Capital GP IV, Ltd. | Cayman Islands | TF Capital IV, Ltd. | 71.05 | N | |
| C-Bridge Healthcare Fund GP IV, L.P. | Cayman Islands | C-Bridge Capital GP IV, Ltd. | 100.00 | N | |
| C-Bridge Healthcare Fund IV, L.P. | Cayman Islands | C-Bridge Healthcare Fund GP IV, L.P. | 100.00 | N | |
| C-Bridge IV Investment Two Limited | British Virgin Islands | C-Bridge Healthcare Fund IV, L.P. | 100.00 | Y | |
| C-Bridge Joint Value Creation Limited | Cayman Islands | Nova Aqua Limited | 100.00 | N | |
| Everest Management Holding Co., Ltd. | Cayman Islands | C-Bridge Joint Value Creation Limited | 86.70 | N | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| (private) | Addresses of individuals are not displayed. | | 5103 | Founder of a discretionary trust who can influence how the trustee exercises his discretion |
| |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a director is interested under sections 317 and 318 | |
|
| |
| 34.
Supplementary information: |
n 25 July 2025, Everest Medicines Limited ("Company"), C-Bridge IV Investment Two Limited ("C-Bridge Two") and the placement agents signed a placing and subscription agreement, pursuant to which C-Bridge Two agreed to sell 22,561,000 shares of the Company to the placees and subscribe for 22,561,000 new shares from the Company. For details, see the announcement of the Company dated 25 July 2025.
|
| 35.
Log/Serial Number of the previous form: |
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
|
|
Date of filing this Form 3A: |
31/07/2025
(dd/mm/yyyy)
|
| |